EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer

Kaylyn L Devlin, Rebecca Smith, Elmar Bucher, Mark Dane, Chloe L Bowman, Eric J Carlson, David Kilburn, Damir Sudar, Heidi S Feiler, Laura M Heiser, Ellen M Langer, James E Korkola

Cell Reports · 2026-01 · 45 (1) · 116826

DOI: 10.1016/j.celrep.2025.116826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026-01. Verfasst von Kaylyn L Devlin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Oregon Health & Science University (OHSU), Portland, OR 97201, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Hepatocyte Growth Factor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NHGRI NIH HHS, Knight Cancer Institute, Oregon Health and Science University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDrug Resistance, NeoplasmHepatocyte Growth FactorHumansFemaleCell Line, TumorTumor MicroenvironmentAnimalsPyrimidinonesPyridonesMice

Stichwörter der Autor:innen

CP: Cancermicroenvironmenttherapeutic resistancetriple negative breast cancertumor heterogeneity

Substanzen

Hepatocyte Growth FactorPyrimidinonestrametinibPyridones

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Oregon Health & Science University (OHSU), Portland, OR 97201, USA.
  • Cancer Early Detection Advanced Research (CEDAR), OHSU, Portland, OR 97201, USA; Division of Oncological Sciences, OHSU, Portland, OR 97201, USA.
  • Quantitative Imaging Systems LLC, Portland, OR 97210, USA.
  • Department of Biomedical Engineering, Oregon Health & Science University (OHSU), Portland, OR 97201, USA; Knight Cancer Institute, OHSU, Portland, OR 97201, USA.
  • Knight Cancer Institute, OHSU, Portland, OR 97201, USA; Cancer Early Detection Advanced Research (CEDAR), OHSU, Portland, OR 97201, USA; Division of Oncological Sciences, OHSU, Portland, OR 97201, USA; Department of Mol…
  • Department of Biomedical Engineering, Oregon Health & Science University (OHSU), Portland, OR 97201, USA; Knight Cancer Institute, OHSU, Portland, OR 97201, USA. Electronic address: korkola@ohsu.edu.

Förderung

  • NCI NIH HHS
  • NHGRI NIH HHS
  • Knight Cancer Institute, Oregon Health and Science University
  • Prospect Creek Foundation
  • National Institutes of Health National Cancer Institute
  • Lady Margaret Hall, University of Oxford
  • National Institutes of Health
  • Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University

Zitieren

APA

Devlin, K. L., Smith, R., Bucher, E., Dane, M., Bowman, C. L., Carlson, E. J., Kilburn, D., Sudar, D., Feiler, H. S., Heiser, L. M., Langer, E. M., & Korkola, J. E. (2026). Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. Cell Reports, 45(1), 116826. https://doi.org/10.1016/j.celrep.2025.116826

Vancouver

Devlin KL, Smith R, Bucher E, Dane M, Bowman CL, Carlson EJ, et al. Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. Cell Reports. 2026;45(1):116826. doi:10.1016/j.celrep.2025.116826

BibTeX
@article{Devlin2026,
  author = {Devlin, Kaylyn L and Smith, Rebecca and Bucher, Elmar and Dane, Mark and Bowman, Chloe L and Carlson, Eric J and Kilburn, David and Sudar, Damir and Feiler, Heidi S and Heiser, Laura M and Langer, Ellen M and Korkola, James E},
  title = {Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer},
  journal = {Cell Reports},
  year = {2026},
  volume = {45},
  number = {1},
  pages = {116826},
  doi = {10.1016/j.celrep.2025.116826}
}
Kostenlos starten →